跳到正文
原文
The Lancet 柳叶刀· Yasaman Vali, Kristy Wonders, Jenny Lee, Guruprasad P Aithal, Rocio Aller, Michael E D Allison, Johanna Arola, Jesus M Banales, Vanesa Bernal-Monterde, Annalisa Berzigotti, Jérôme Boursier, Clifford A Brass, Elisabetta Bugianesi, Jose Luis Calleja, Jeremy F Cobbold, Helena Cortez-Pinto, Javier Crespo, Susan Davies, Ann Driessen, Kevin L Duffin, Mattias Ekstedt, Daniel Forton, Céline Fournier-Poizat, Sven Francque, Andreas Geier, Joseph Gogain, Annette S H Gouw, Hannes Hagström, Adriaan G Holleboom, Prodromos Hytiroglou, Morten Karsdal, Carolin Lackner, Diana J Leeming, Luca Miele, George Papatheodoridis, Valerie Paradis, Michael Pavlides, Juan M Pericàs, Salvatore Petta, Vlad Ratziu, Manuel Romero-Gomez, Jörn M Schattenberg, Detlef Schuppan, Rambabu Surabattula, Ana Paula Silva, Mette Skalshøi Kjær, Beate K Straub, Gianluca Svegliati-Baroni, Dina Tiniakos, Maria Manuela Tonini, Richard Torstenson, Luca V C Valenti, Joanne Verheij, Jeremy Magnanensi, Rebeca Mayo, David Wenn, Hannele Yki-Järvinen, Carla Yunis, Patrick M Bossuyt, Quentin M Anstee, LITMUS Investigators·· 21 天前AI 评分45

LITMUS 多中心诊断准确性研究:多标志物组合检测 at-risk MASH 显示潜力

[Articles] Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study

AI 导读

LITMUS 前瞻性多中心诊断准确性研究显示,与组织学相比,单一标志物检测 at-risk MASH 的表现有限且不稳定,而多标志物组合尤其是蛋白组学组合表现出较强诊断性能。作者认为,这些结果可支持 MASLD 无创检测策略的选择与实施,并为未来临床指南、监管评估和临床试验设计提供参考。

来源:The Lancet 柳叶刀 · thelancet.com